InMed to merge with Mentari; pre-Merger InMed holders to own ~1.51% of combined company

InMed Pharmaceuticals Inc.

Merger: InMed shareholders to own ~1.51% of combined entity; Mentari stockholders ~98.49%.
Concurrent $290M private placement led by Fairmount; funds operations through 2028.
Mentari's lead programs: MT-001 (anti-PACAP) and MT-002 (anti-CGRP x PACAP bispecific) targeting migraine prevention.
Pre-Merger InMed shareholders receive Contingent Value Rights (CVRs) for net proceeds from legacy asset sales.
Closing conditions include $150M+ pre-closing financing, shareholder approvals, and Nasdaq listing.

item 1.01item 5.01item 5.02item 7.01item 9.01

Featured in Daily 8-K Digest

Selected #1 for 2026-05-19. Read digest

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.